Spark Therapeutics to Participate in Multiple Upcoming Conferences
02 nov. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results
31 oct. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
12 oct. 2017 16h51 HE
|
Spark Therapeutics, Inc.
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States ...
Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy
12 oct. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Participate in Multiple Conferences in October
03 oct. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer
25 sept. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Enters into Licensing Agreement with Genethon
20 sept. 2017 07h30 HE
|
Spark Therapeutics, Inc.; Genethon
PHILADELPHIA and EVRY, France, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic...
Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision
06 sept. 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Participate in Multiple Conferences in September
30 août 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
11 août 2017 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...